B7-33 Peptide: A Functional Selective RXFP1 Agonist for Fibrosis and Cardiovascular Research
Discover the potential of B7-33 peptide in treating fibrotic diseases and improving cardiovascular health.
Get a Quote & SampleProduct Core Value
B7-33 Peptide
B7-33 peptide is a synthetic analog of H2 relaxin that acts as a functionally selective agonist for the RXFP1 receptor. This selectivity allows it to preferentially activate the pERK pathway over the cAMP pathway, mitigating the tumor-promoting effects associated with full cAMP activation by native relaxin while retaining beneficial anti-fibrotic properties. It represents a significant advancement in the development of targeted peptide therapies.
- Explore the B7-33 peptide mechanism of action to understand its targeted therapeutic approach to fibrosis and cardiovascular conditions.
- Understand the critical differences between B7-33 peptide vs H2 relaxin, particularly concerning pathway activation and side effect profiles.
- Investigate B7-33 as a novel solution for fibrosis treatment peptide, offering a more targeted approach than current therapies.
- Learn how B7-33 is being utilized in cutting-edge cardiovascular research to improve patient outcomes.
Key Advantages
Selective Receptor Activation
B7-33 peptide's functional selectivity for the RXFP1 receptor ensures targeted action, minimizing off-target effects often seen with less specific compounds. This precision is key for its application in complex disease states.
Therapeutic Potential in Fibrosis
The peptide's potent anti-fibrotic peptide therapy capabilities make it a promising candidate for conditions characterized by excessive tissue scarring, potentially offering a new avenue for treatment.
Reduced Risk Profile
Unlike H2 relaxin, B7-33 peptide does not promote tumor growth, making it a safer option for long-term therapeutic use in various disease management strategies.
Key Applications
Fibrosis Research
B7-33 is a valuable tool for fibrosis research, allowing scientists to investigate mechanisms of tissue remodeling and develop new antifibrotic strategies.
Cardiovascular Health
Its potential role in improving heart function and reducing cardiac fibrosis positions B7-33 as a key peptide in cardiovascular health advancements.
Pulmonary Disease Treatment
The peptide's efficacy in preclinical models of pulmonary fibrosis highlights its potential for developing treatments for pulmonary fibrosis.
Oncology and Regenerative Science
Exploration into B7-33's interaction with tumor microenvironments and its regenerative potential opens new avenues in oncology research and regenerative medicine.